title: [Update of recommendations on the use of palivizumab as prophylaxis in RSV infections].
abstract: The Standards Committee of the Spanish Neonatology Society (SENeo) considers that the new document from the American Academy of Pediatrics, including recommendations for palivizumab use to prevent serious infections produced by the Respiratory Syncytial Virus (RSV), provides no new scientific evidence which would justify the modification of the current recommendations of the SENeo. However, some adjustments to the criteria of the existing recommendations are proposed to reduce the cost of the drug by its correct and judicious management.
authors.affiliation: Servicio de Neonatología, Hospital Clínic, Facultad de Medicina, Barcelona, España. Electronic address: jfiguer@clinic.ub.es.
authors.forename: J
authors.initials: J
authors.lastname: Figueras Aloy
authors.affiliation: Servicio de Neonatología, Hospital Clínic, Facultad de Medicina, Barcelona, España.
authors.forename: X
authors.initials: X
authors.lastname: Carbonell Estrany
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D000069455:Palivizumab / Q000627:therapeutic use*; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*
chemical_list: D000998:Antiviral Agents; D000069455:Palivizumab
keywords: Bronchiolitis; Bronquiolitis; Palivizumab; Prematuros; Preterm infants; Prevención; Prevention; Respiratory syncytial virus; Virus respiratorio sincitial